148 related articles for article (PubMed ID: 22959509)
21. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
[TBL] [Abstract][Full Text] [Related]
22. miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma.
Kontos CK; Tsiakanikas P; Avgeris M; Papadopoulos IN; Scorilas A
Mol Diagn Ther; 2017 Aug; 21(4):453-464. PubMed ID: 28405803
[TBL] [Abstract][Full Text] [Related]
23. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
24. Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia.
Humplikova L; Kollinerova S; Papajik T; Pikalova Z; Holzerova M; Prochazka V; Divoka M; Modriansky M; Indrak K; Jarosova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):284-93. PubMed ID: 24026141
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
[TBL] [Abstract][Full Text] [Related]
26. MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5.
Renjie W; Haiqian L
Cancer Lett; 2015 Jan; 356(2 Pt B):568-78. PubMed ID: 25305447
[TBL] [Abstract][Full Text] [Related]
27. Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma.
Li J; Li M; Gao F; Ge X
Cancer Biomark; 2017; 18(1):11-17. PubMed ID: 27802201
[TBL] [Abstract][Full Text] [Related]
28. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
31. [Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells].
Zang MR; Li F; An G; Xie ZQ; Li CH; Yu Z; Xu Y; Qiu LG; Hao M
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1100-3. PubMed ID: 22781767
[TBL] [Abstract][Full Text] [Related]
32. BCL2 and miR-15/16: from gene discovery to treatment.
Pekarsky Y; Balatti V; Croce CM
Cell Death Differ; 2018 Jan; 25(1):21-26. PubMed ID: 28984869
[TBL] [Abstract][Full Text] [Related]
33. MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN.
Yuan J; Su Z; Gu W; Shen X; Zhao Q; Shi L; Jin C; Wang X; Cong H; Ju S
Cancer Biomark; 2019; 24(3):279-289. PubMed ID: 30883341
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of microRNA-15a-3p is correlated with clinical outcome and negatively regulates cancer proliferation and migration in human osteosarcoma.
Shi J; Fu Q; Yang P; Liu H; Ji L; Wang K
J Cell Biochem; 2018 Jan; 119(1):1215-1222. PubMed ID: 28722268
[TBL] [Abstract][Full Text] [Related]
35. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
Wang Z; Cai H; Lin L; Tang M; Cai H
Pediatr Blood Cancer; 2014 Feb; 61(2):206-10. PubMed ID: 24038809
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients.
Bao Y; Wei M; Ji X
J Clin Lab Anal; 2020 May; 34(5):e23168. PubMed ID: 31908003
[TBL] [Abstract][Full Text] [Related]
37. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Jagannath S; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Cowan JM; Anderson KC
Leukemia; 2007 Jan; 21(1):151-7. PubMed ID: 17096017
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma.
Unno K; Zhou Y; Zimmerman T; Platanias LC; Wickrema A
Leuk Lymphoma; 2009 Nov; 50(11):1865-71. PubMed ID: 19883314
[TBL] [Abstract][Full Text] [Related]
40. Gene expression and single nucleotide polymorphism array analyses of spindle cell lipomas and conventional lipomas with 13q14 deletion.
Bartuma H; Nord KH; Macchia G; Isaksson M; Nilsson J; Domanski HA; Mandahl N; Mertens F
Genes Chromosomes Cancer; 2011 Aug; 50(8):619-32. PubMed ID: 21563233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
